Drug Price Watchdog Making Unfair Decisions, Indian Industry Lobby Says
This article was originally published in The Pink Sheet Daily
Lack of transparency in price setting, misapplication of the Spurious Drugs law and a new requirement that already-approved fixed-dose combinations be treated as new drugs are high on the grievance list.
You may also be interested in...
NEW DELHI - Grappling with increasing incidents of spurious drugs, the Indian health ministry has proposed an incentive scheme for "whistle blowers" who provide credible information and help the government in confiscating fake drugs, cosmetics or medical devices
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.
With an unrestricted label and once-daily dosing, rivaroxaban will do battle with Boehringer-Ingelheim's dabigatran, which is dosed twice a day but can claim superior efficacy to warfarin in the atrial fibrillation population.